tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AU:PER Stock Latest News

Percheron Advances HMBD-002 into Innovative Phase II After Positive Phase I Cancer Data
Company AnnouncementsPercheron Advances HMBD-002 into Innovative Phase II After Positive Phase I Cancer Data
3d ago
Percheron Therapeutics Director Increases On-Market Shareholding
PremiumCompany Announcements
Percheron Therapeutics Director Increases On-Market Shareholding
1M ago
Percheron Therapeutics Director James Garner Increases Shareholding via On-Market Purchase
PremiumCompany Announcements
Percheron Therapeutics Director James Garner Increases Shareholding via On-Market Purchase
1M ago
Percheron Therapeutics Updates Corporate Presentation with New Program Insights
PremiumCompany Announcements
Percheron Therapeutics Updates Corporate Presentation with New Program Insights
3M ago
Percheron Therapeutics Advances HMBD-002 with Positive Trial Results
PremiumCompany Announcements
Percheron Therapeutics Advances HMBD-002 with Positive Trial Results
3M ago
Percheron Therapeutics Reports Strong Shareholder Support at AGM
PremiumCompany AnnouncementsPercheron Therapeutics Reports Strong Shareholder Support at AGM
3M ago
Percheron Therapeutics Unveils Future Plans at AGM
Premium
Company Announcements
Percheron Therapeutics Unveils Future Plans at AGM
3M ago
Percheron Therapeutics Releases Final Results of Phase I Clinical Trial for HMBD-002
Premium
Company Announcements
Percheron Therapeutics Releases Final Results of Phase I Clinical Trial for HMBD-002
4M ago
Percheron Therapeutics Advances HMBD-002 Cancer Therapy Development
PremiumCompany Announcements
Percheron Therapeutics Advances HMBD-002 Cancer Therapy Development
4M ago
Percheron Therapeutics Strengthens Leadership Team to Advance Cancer Therapy
PremiumCompany Announcements
Percheron Therapeutics Strengthens Leadership Team to Advance Cancer Therapy
4M ago
Percheron Therapeutics Announces 2025 Annual General Meeting
PremiumCompany Announcements
Percheron Therapeutics Announces 2025 Annual General Meeting
4M ago
Percheron Therapeutics Secures $1.43 Million R&D Rebate to Advance Oncology Program
PremiumCompany Announcements
Percheron Therapeutics Secures $1.43 Million R&D Rebate to Advance Oncology Program
5M ago
Percheron Therapeutics Announces Date for 2025 AGM and Releases Annual Report
PremiumCompany AnnouncementsPercheron Therapeutics Announces Date for 2025 AGM and Releases Annual Report
5M ago
Percheron Therapeutics Reinforces Governance Standards with Latest Statement
Premium
Company Announcements
Percheron Therapeutics Reinforces Governance Standards with Latest Statement
5M ago
Percheron Therapeutics Unveils Promising Preclinical Data for HMBD-002 in Triple-Negative Breast Cancer
Premium
Company Announcements
Percheron Therapeutics Unveils Promising Preclinical Data for HMBD-002 in Triple-Negative Breast Cancer
6M ago
Percheron Therapeutics Secures License for Promising Cancer Drug HMBD-002
PremiumCompany Announcements
Percheron Therapeutics Secures License for Promising Cancer Drug HMBD-002
6M ago
Percheron Therapeutics’ HMBD-002 Shows Promise in Enhancing Radiotherapy for Cancer
PremiumCompany Announcements
Percheron Therapeutics’ HMBD-002 Shows Promise in Enhancing Radiotherapy for Cancer
6M ago
Percheron Therapeutics Director Increases Stake
PremiumCompany Announcements
Percheron Therapeutics Director Increases Stake
7M ago
Powerhouse Ventures Ceases Substantial Holding in Percheron Therapeutics
PremiumCompany Announcements
Powerhouse Ventures Ceases Substantial Holding in Percheron Therapeutics
7M ago
Percheron Therapeutics Updates Stakeholders on HMBD-002 and Financials
PremiumCompany AnnouncementsPercheron Therapeutics Updates Stakeholders on HMBD-002 and Financials
7M ago
Percheron Therapeutics Secures License for Promising Cancer Drug HMBD-002
Premium
Company Announcements
Percheron Therapeutics Secures License for Promising Cancer Drug HMBD-002
7M ago
Percheron Therapeutics Initiates Trading Halt Ahead of Licensing Announcement
Premium
Company Announcements
Percheron Therapeutics Initiates Trading Halt Ahead of Licensing Announcement
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >